Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (301-310 of 436) with videos related to

Pageof 44
Sort By:
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Blood|March 2, 2017
More than 1 <i>TP53</i> abnormality is a dominant characteristic of pure erythroid leukemiaGuillermo Montalban-Bravo, Christopher B Benton, Sa A Wang, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers|November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center ExperienceDavid McCall, Shaikha Alqahtani, Moriah Budak, et al.
American Journal of Hematology|April 26, 2021
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Gautam Borthakur, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|November 23, 2016
Dorsal column myelopathy after intrathecal chemotherapy for leukemiaChelsea C Pinnix, Linda Chi, Elias J Jabbour, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Pageof 44

Showing results (301-310 of 436) with videos related to

Sort By:
Pageof 44
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Blood|March 2, 2017
More than 1 <i>TP53</i> abnormality is a dominant characteristic of pure erythroid leukemiaGuillermo Montalban-Bravo, Christopher B Benton, Sa A Wang, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers|November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center ExperienceDavid McCall, Shaikha Alqahtani, Moriah Budak, et al.
American Journal of Hematology|April 26, 2021
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Gautam Borthakur, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|November 23, 2016
Dorsal column myelopathy after intrathecal chemotherapy for leukemiaChelsea C Pinnix, Linda Chi, Elias J Jabbour, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Pageof 44